DK3192874T3 - Virusoprensning - Google Patents

Virusoprensning Download PDF

Info

Publication number
DK3192874T3
DK3192874T3 DK16002644.9T DK16002644T DK3192874T3 DK 3192874 T3 DK3192874 T3 DK 3192874T3 DK 16002644 T DK16002644 T DK 16002644T DK 3192874 T3 DK3192874 T3 DK 3192874T3
Authority
DK
Denmark
Prior art keywords
cleanup
virus
virus cleanup
Prior art date
Application number
DK16002644.9T
Other languages
English (en)
Inventor
Richard Truran
Robert Buckley
Pippa Radcliffe
James Miskin
Kyri Mitrophanous
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40940324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3192874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of DK3192874T3 publication Critical patent/DK3192874T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16002644.9T 2008-06-18 2009-06-18 Virusoprensning DK3192874T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7368508P 2008-06-18 2008-06-18
EP09766124.3A EP2307551B1 (en) 2008-06-18 2009-06-18 Purification of retroviral vectors

Publications (1)

Publication Number Publication Date
DK3192874T3 true DK3192874T3 (da) 2019-12-16

Family

ID=40940324

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16002644.9T DK3192874T3 (da) 2008-06-18 2009-06-18 Virusoprensning
DK09766124.3T DK2307551T3 (da) 2008-06-18 2009-06-18 Oprensning af retrovirale vektorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09766124.3T DK2307551T3 (da) 2008-06-18 2009-06-18 Oprensning af retrovirale vektorer

Country Status (8)

Country Link
US (1) US9169491B2 (da)
EP (2) EP3192874B1 (da)
JP (2) JP5615271B2 (da)
CN (2) CN102124115B (da)
DK (2) DK3192874T3 (da)
ES (2) ES2618851T3 (da)
PL (2) PL2307551T3 (da)
WO (1) WO2009153563A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340102B (es) * 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.
JP5965392B2 (ja) 2010-05-28 2016-08-03 オックスフォード バイオメディカ （ユーケー） リミテッド 脳へのレンチウイルスベクターの送達
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
PL2782997T3 (pl) 2011-11-24 2018-06-29 Genethon Skalowalny układ do wytwarzania wektora lentiwirusowego zgodny z przemysłowymi zastosowaniami farmaceutycznymi
US20140349403A1 (en) * 2011-12-12 2014-11-27 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
EP2802649B1 (en) 2012-01-09 2017-08-09 Sanofi Pasteur Biologics, LLC Purification of herpes virus
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
PT3889173T (pt) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc Gene do fator viii otimizado
KR102200278B1 (ko) * 2013-03-15 2021-01-07 더 칠드런스 호스피탈 오브 필라델피아 무혈청 현탁 세포 배양 시스템에서 재조합 렌티바이러스 벡터를 생성하기 위한 확대가능한 제작 방법
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
CN104371982A (zh) * 2014-10-21 2015-02-25 武汉维诺赛生物技术有限公司 一种慢病毒的纯化方法
JP6718444B2 (ja) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） Ｂｏｂ１に対して指向されるＴ細胞レセプターおよびその使用
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
JP2018510627A (ja) 2015-03-10 2018-04-19 レイデン ユニバーシティ メディカル センター メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
WO2017091786A1 (en) 2015-11-23 2017-06-01 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
RS63548B1 (sr) 2016-02-01 2022-09-30 Bioverativ Therapeutics Inc Optimizovani geni faktora viii
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
US20190225956A1 (en) 2016-05-10 2019-07-25 United States Government As Represented By The Department Of Veterans Affairs Lentiviral delivery of crispr/cas constructs that cleave genes essential for hiv-1 infection and replication
GB201614050D0 (en) * 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
MA50877A (fr) 2017-11-21 2020-09-30 Bayer Healthcare Llc Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
CN111836892A (zh) 2017-12-21 2020-10-27 克里斯珀医疗股份公司 用于治疗2a型乌谢尔综合征的材料和方法
CA3084633A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
FI3633040T3 (fi) 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
JOP20200253A1 (ar) * 2018-04-05 2020-10-04 Univ Oxford Innovation Ltd تركيبات وطرق لعلاج الحثل البقعي
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
JP7315590B2 (ja) 2018-06-12 2023-07-26 クビオ・ホールディングス・リミテッド ウイルスと抗原の精製及び結合
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
KR20210053285A (ko) * 2018-08-16 2021-05-11 스페이스크래프트 세븐, 엘엘씨 바이러스 벡터의 생산 방법
WO2020183374A1 (en) 2019-03-10 2020-09-17 Axovant Sciences Gmbh Gene therapy compositions and methods for treating parkinson's disease
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
KR20220097492A (ko) 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 생산 시스템
JP2023513303A (ja) 2020-02-13 2023-03-30 オックスフォード バイオメディカ（ユーケー）リミテッド レンチウイルスベクターの製造
US20230118587A1 (en) 2020-03-13 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral Vectors
AU2021264465A1 (en) 2020-04-27 2022-12-15 University Of Iowa Research Foundation Compositions and methods for the treatment of cystic fibrosis
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
CA3188923A1 (en) * 2020-08-13 2022-02-17 Michael Sean BURNHAM Methods for producing clinical-grade lentiviral vector
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
CN112899242A (zh) * 2021-02-03 2021-06-04 苏州博腾生物制药有限公司 慢病毒纯化工艺
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
WO2023074877A1 (ja) 2021-10-29 2023-05-04 Ａｇｃ株式会社 細胞添加用組成物
WO2023085382A1 (ja) 2021-11-12 2023-05-19 Ａｇｃ株式会社 ウイルスの精製方法
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78703A (en) 1985-05-10 1993-02-21 Benzon Alfred Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
CA2104396C (en) 1991-02-19 2000-10-10 Jiing-Kuan Yee Viral particles having altered host range
EP0738319A4 (en) * 1994-01-12 2000-03-29 Genetic Therapy Inc Purification of retroviral vectors
WO1995025789A1 (en) 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2263154A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
IL129017A0 (en) 1996-10-17 2000-02-17 Oxford Biomedica Ltd Retroviral vectors
ATE550429T1 (de) * 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
KR20010074493A (ko) 1998-05-22 2001-08-04 찰스 굿맨 레트로바이러스 전달 시스템
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (da) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
CA2478932A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
US20050196854A1 (en) 2002-05-14 2005-09-08 Konz John O.Jr. Methods of adenovirus purification
AU2003260769A1 (en) 2002-09-03 2004-03-29 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
WO2004098531A2 (en) 2003-05-05 2004-11-18 Virxsys Corporation Increased transduction using abc transporter substrates and/or inhibitors
SE0302509D0 (sv) 2003-09-19 2003-09-19 Amersham Biosciences Ab Matrix for separation of polyethers and method of separation
RU2006117304A (ru) * 2003-10-20 2007-12-10 Нсджин А/С (Dk) Генная терапия болезни паркинсона iv vivo
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
EP2091966A2 (en) * 2006-12-01 2009-08-26 Oxford BioMedica (UK) Limited Promoter construct
NZ578873A (en) 2007-03-01 2012-01-12 Wellstat Ophthalmics Corp Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation
US20110130473A1 (en) * 2007-11-13 2011-06-02 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers

Also Published As

Publication number Publication date
JP2014237661A (ja) 2014-12-18
ES2762864T3 (es) 2020-05-26
US20090325284A1 (en) 2009-12-31
WO2009153563A1 (en) 2009-12-23
CN102124115A (zh) 2011-07-13
DK2307551T3 (da) 2017-03-20
CN103993040B (zh) 2018-02-13
EP3192874B1 (en) 2019-10-16
PL2307551T3 (pl) 2017-07-31
JP5615271B2 (ja) 2014-10-29
ES2618851T3 (es) 2017-06-22
PL3192874T3 (pl) 2020-06-29
US9169491B2 (en) 2015-10-27
EP2307551A1 (en) 2011-04-13
EP3192874A1 (en) 2017-07-19
JP6002720B2 (ja) 2016-10-05
JP2011524887A (ja) 2011-09-08
EP2307551B1 (en) 2016-12-14
CN102124115B (zh) 2020-03-03
CN103993040A (zh) 2014-08-20

Similar Documents

Publication Publication Date Title
DK3192874T3 (da) Virusoprensning
DK2370461T3 (da) Glucagonanaloger
DK2370462T3 (da) Glucagon-analoger
BRPI0907376A2 (pt) Fotobiorretador
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
DK3444343T3 (da) Polypeptider
BRPI0922480A2 (pt) compósitos de nanocalcita
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
DK2342454T3 (da) Vindkraftanlæg
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
DK2379557T3 (da) Aminopyrazol-forbindelse
DE602008003970D1 (de) Strahlstromkalibriersystem
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
BRPI0915562A2 (pt) tamis melhorado
BRPI0915442A2 (pt) tamis melhorado
BRPI0907522A2 (pt) biarlamidas
BRPI0909634A2 (pt) 2-aminoquinolinas
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
BRPI0909637A2 (pt) 2-aminoquinolinas
DE112009000183A5 (de) Sicherheitsvorreiber